PORTFOLIO
A life science venture creation and management company focused on pharmaceuticals, devices and diagnostics technologies that can be commercialized, partnered or licensed in 36 months or less. We are run by life science & biomedical Professionals with experience identifying and commercializing innovative healthcare products. We currently manag:
 |
Tranverse Medical Inc is an early stage medical device company focused on the development of the Point-Guard™ Embolic Protection and Capture Device for cerebral and distal embolic protection during percutaneous interventional and open cardiac surgery (Cardiovascular) procedures. |
 |
Vanquish Oncology, Inc. is a drug (Small Molecule Cancer Drug) development company focused on targeting molecular defects in specific cancer cells to create targeted personalized oncology therapeutics to take advantage of cancers that have aberrant proteins that can be screened to establish drugs that will have improved efficacy. The Company’s product programs (Procaspase-3 Activation Program, RAPID Program and Combi Program) and lead product candidate have unique mechanisms of action (MOA) that will allow them to be efficacious across multiple tumor types through target specific induction of apoptosis (cell death) in human cancer cells. Vanquish has pre-clinical data that demonstrates the Company's lead product candidate to be well tolerated and efficacious in two animal models, ex situ human cancer cells and human cell lines. Several aspects of pre-clinical IND development have been de-risked and the Company is poised to initiate IND enabling development activities. The Company will develop this product through Phase I with the intent to partner/sell the program for later stage clinical trials and commercialization. |
|
